CCGA Study
Biomarker Discovery & Validation
Observational Case-Control StudyCompleted
Key Facts
Indication
Biomarker Discovery & Validation
Phase
Observational Case-Control Study
Status
Completed
Company
About GRAIL
GRAIL's mission is to alleviate the global burden of cancer through early detection. The company has achieved a leading position in the MCED space with its Galleri test, supported by a robust clinical program involving over 385,000 participants, including landmark trials like NHS-Galleri. Its strategy centers on generating definitive clinical evidence to drive widespread adoption, secure reimbursement, and integrate its test into routine clinical care for adults at elevated risk.
View full company profile